



an Open Access Journal by MDPI

Bioassay Platforms for the Disclosure of the Pharmaceutical Potential of Marine Natural Products

Guest Editors:

Dr. Nuzzo Genoveffa

Bio-Organic Chemistry Research Group, Consiglio Nazionale delle Ricerche - Istituto di Chimica Biomolecolare, Via Campi Flegrei 34, 80078 Pozzuoli, Napoli, Italy

Dr. Carmela Gallo

Institute of Biomolecular Chemistry, Cnr Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Italy

Deadline for manuscript submissions:

closed (31 August 2021)

Message from the Guest Editors

Dear Colleagues,

Marine organisms have proven to be a rich source of diverse natural products with distinctive antibacterial, antifungal, antiviral, antiparasitic, antitumor, antiinflammatory, antioxidant, and immunomodulatory activities. Various marine metabolites have shown drug-like physicochemical properties through specific mechanisms of action. A bioassay-guided fractionation is usually conducted for the identified of the pharmaceutical potential of marine natural products, but other strategies can be applied. To purify novel secondary metabolites, it is crucial to develop efficient screening platforms to recognize the samples with the most promise early in the workflow so that resources can be efficiently and cost-effectively used. A screening platform of bioactive compounds may involve a huge number of analysis assays for assessing the potential of biological extracts or molecules from marine organisms. The improvement of the whole procedure needs innovative assay platforms that can be used to help to automate testing processes with greater throughput, speed, reliability, and reproducibility.



mdpi.com/si/41340

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)